Revenues (Tables)

6 Months Ended

Jun. 30, 2021

Revenue from Contract with Customer [Abstract]

The following table presents the Company's revenues disaggregated

The following table presents the Company's revenues disaggregated by outsourced manufacturing, sterile and non-sterile regulatory environments for the three months and six months ended June 30, 2021 and 2020. 

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
Drug Development & Commercialization:
Outsourced Manufacturing	$	1,275,474	$	721,435	$	2,608,153	$	1,228,719
Compounded Pharmaceuticals:
Sterile	$	1,654,686	$	1,982,506	$	3,279,697	$	5,033,621
Non-Sterile		1,081,144		1,222,401		2,231,986		2,327,212
Total Compounded Pharmaceuticals Revenues	$	2,735,830	$	3,204,907	$	5,511,683	$	7,360,833
Total	$	4,011,304	$	3,926,342	$	8,119,836	$	8,589,552

The Company's revenues relating to its FDA approved product SYMJEPI are dependent on the USWM Agreement with USWM, which replaced Sandoz in May 2020 in connection with the above-mentioned termination of the Sandoz Agreement, and the Company’s revenues relating to pharmacy formulations rely, in large part, on sales generated from clinics and hospital customers. Adverse economic conditions pose a risk that the Company’s customers may reduce or cancel spending, which would impact the Company’s revenues. The COVID-19 outbreak has adversely affected revenues from sales of USC products, in part due to reductions or cancellations of elective surgeries and reduction in office visits to physicians' offices, healthcare facilities or clinics by patients, and the resulting decreased demand by USC’s customers for certain of USC’s products, and will likely continue to adversely affect revenues from sales of products to such customers for a period of time which cannot be predicted.

The following table presents the Company's revenue disaggregated by end market for the three months and six months ended June 30, 2021 and 2020.

	Three Months Ended June 30				Six Months Ended June 30
	2021		2020		2021		2020
Drug Development and Commercialization:
Distribution Channel	$	1,275,474	$	721,435	$	2,608,153	$	1,228,719
Compounded Pharmaceuticals:
Clinics/Hospitals	$	2,682,100	$	3,013,030	$	5,408,837	$	6,940,458
Direct to Patients		53,730		191,877		102,846		420,375
Total Compounded Pharmaceuticals Revenues	$	2,735,830	$	3,204,907	$	5,511,683	$	7,360,833
Total	$	4,011,304	$	3,926,342	$	8,119,836	$	8,589,552